Related Experiment Video

Updated: Jul 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Treating hepatitis C in African Americans

Lennox J Jeffers1

  • 1Department of Medicine, Center for Liver Diseases, Veterans Affairs Medical Center, Miami, FL 33125, USA. l.jeffers@miami.edu

Liver International : Official Journal of the International Association for the Study of the Liver
|March 16, 2007
PubMed

Insights

African Americans with chronic hepatitis C show different disease patterns and respond less effectively to treatment. Improved therapeutic strategies are needed to enhance outcomes for this population.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Clinical Epidemiology

Background:

  • Chronic hepatitis C (HCV) exhibits distinct epidemiological patterns, natural history, and treatment responses in African Americans compared to other ethnic groups.
  • Factors contributing to these differences include transmission modes, viral kinetics, immune responses, and demographic characteristics.

Purpose of the Study:

  • To review literature and expert opinions from 1990-2005 on hepatitis C virus (HCV) infection in African Americans.
  • To identify differences in presentation, therapeutic response, and provide treatment recommendations.

Main Methods:

  • Literature review
  • Expert opinion synthesis

Main Results:

  • HCV epidemiology in African Americans is linked to socioeconomic status and high-risk behaviors.
  • Race may influence disease progression, with African Americans potentially clearing HCV less efficiently.
  • Impaired immune responsiveness in African Americans may affect necro-inflammatory activity and cirrhosis progression.
  • Therapy-naive African Americans exhibit lower sustained virologic response rates to standard treatments.

Conclusions:

  • Future strategies should focus on optimizing current therapies, developing medications with improved safety profiles, and exploring novel molecular treatments.
  • Enhanced treatment protocols are crucial for improving outcomes in African American patients with HCV.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...